摘要
目的:探讨血清C-反应蛋白(CRP)的测定在肝硬化和肝癌中的临床应用价值。方法:采用散射比浊法测定52例肝硬化、30例肝癌以及30例正常对照者的血清CRP水平,同时采用放免法检测各组血清甲胎蛋白(AFP)含量,并与CRP结果进行对比分析。结果:各疾病组患者血清CRP水平明显高于正常对照组(P<0.001,P<0.05),而且肝癌组>肝硬化组,肝硬化失代偿组>肝硬化代偿组,差异越大,预后越差。单独检测血清CRP和AFP对肝癌诊断的灵敏度分别是86.7%和80.0%;特异性分别是65.8%和78.0%;以CRP和AFP至少1项阳性作为判断标准,灵敏度上升为96.7%。结论:检测肝硬化、肝癌患者血清CRP含量,有助于发现和了解肝内炎症活动及肝细胞受损的状况,为临床诊断和治疗提供重要的参考依据。单独检测血清CRP不是诊断肝癌的理想指标,但血清CRP和AFP的联合检测对肝癌诊断有互补作用。
Objective：To investigate the clinical application value of detecting serum c-reative protein （CRP）in patients with hepatic cirrhosis and liver cancer, Methods：CRP in the serum of 52 patients with hepatic cirrhosis,30 patients with liver cancer and 30 from the normal control were detected by nephelometry, alpha-fetoprotein （AFP） concentration was detected by radio-immunoassay, and the results of the two indicators were compared. Results：High positive rate of CRP level was observed in all disease groups as compared with that of the control group （P 〈 0. 001 ,P 〈 0. 05 ） ,and CRP level of liver cancer group was higher than that of the hepatic cirrhosis group and hepatic cirrhosis deeompensation group was higher than that of hepatic cirrhosis compensation group, The larger the difference was, the worse the prognosis was, If CRP or AFP in the serum was detected alone, the sensitivity of diagnosing liver cancer was 86, 7% and 80.0% respectively,the specificity was 65.8% and 78.0%. With CRP and AFP at least one positive as judgement standard,the sensitivity went up to 96. 7%. Conclusion：Detecting the coneent of serum CRP of patients with hepatieeirrhosis and liver cancer is helpful to discover and understand the inflammatory activity in the liver and the impared condition of hepatic cells,and provide important reference on clinical diagnosis and therapy. Detecting serum CRP alone is not an ideal index to diagnose liver cancer,but serum CRP and AFP detected together has supplementary effect on diagnosing liver cancer.
出处
《华北国防医药》
2007年第3期57-59,共3页
Medical Journal of Beijing Military Region
关键词
肝硬化
肝肿瘤
C-反应蛋白
Hepatic cirrhosis
Liver tumor
C-reactive protein
